Ilypsa, Inc. Appoints Samuel R. Saks, M.D. To Board Of Directors

SANTA CLARA, Calif.--(BUSINESS WIRE)--Ilypsa, Inc., a privately-held biopharmaceutical company pioneering novel non-absorbed drugs for renal and metabolic disorders, today announced that Samuel R. Saks, M.D., Chief Executive Officer, Jazz Pharmaceuticals, will be joining Ilypsa’s Board of Directors.

Back to news